Skip to content

Rigel Pharmaceuticals RIGL Other Non-Current Assets

Other Non-Current Assets at other companies

Amgen logo
AmgenAMGN
$12.76B+12.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$751K+130%
Nuvation Bio logo
Nuvation BioNUVB
$3.82M-42.2%
Regenxbio logo
RegenxbioRGNX
$5.51M+84.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$143K-51.2%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$4.94M-11.1%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's other non-current assets?
Rigel Pharmaceuticals (RIGL) reported other non-current assets of $2.36M in Q1 2026.
How has Rigel Pharmaceuticals's other non-current assets changed year-over-year?
Rigel Pharmaceuticals's other non-current assets increased by 55.5% year-over-year, from $1.52M to $2.36M.
What is the long-term trend for Rigel Pharmaceuticals's other non-current assets?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's other non-current assets has grown at a 18.3% compound annual growth rate (CAGR), from $824K to $1.91M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.